+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 30Years - 80Years
All Genders
ID07432958

Evaluating Two Doses of AP-472 Added to Levodopa for Motor Fluctuations in Parkinsons Disease A Double-Blind Placebo-Controlled Phase 2 Study

Led by Appello Pharmaceuticals, Inc. · Updated on 2026-10-28

150

Participants Needed

30

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of two different doses of the drug AP-472 as an add-on treatment to levodopa in people with Parkinsons disease who experience motor fluctuations. This Phase 2 study aims to compare these doses with a placebo over a 14-week period to better understand how AP-472 affects motor symptoms when combined with standard levodopa therapy. Participants will be randomly assigned to receive either 100 mg or 300 mg of AP-472 daily, or a placebo, without knowing which treatment they are receiving. The study includes a screening phase, a 4-week period with stable Parkinsons medications, and a 12-week treatment phase during which some adjustments to levodopa dosing are allowed if necessary. During their participation, individuals will be closely monitored with assessments including motor diaries to track daily OFF time, various Parkinsons disease rating scales, and sleepiness questionnaires. The primary focus is on changes in average daily OFF time after 12 weeks of treatment. Safety and effectiveness will be evaluated throughout, with the entire study lasting about 14 weeks from start to finish.

CONDITIONS

Brief Title

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

Research Team

A

Annie Blobaum, Ph.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here